表紙
市場調查報告書
商品編碼
961504

血友病的全球市場(按治療方案,類型,治療):討論/預測,新冠狀病毒感染的潛在影響(COVID-19)(2020-2024)

Global Hemophilia Market (By Treatment Regimen, Type & Therapy): Insights & Forecast with Potential Impact of COVID-19 (2020-2024)

出版日期: | 出版商: Koncept Analytics | 英文 131 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

預計到2020年至2024年,全球血友病市場將以5.61%的複合年增長率增長,到2024年將達到138.6億美元。在醫療成本增加和特定血友病患者數量在推動市場增長的同時,他們可能會面臨諸如高昂的治療費用和對轉換治療方法的抵抗之類的挑戰。根據治療方案,預防性治療的比例更高,其次是應付性治療(按需)。按治療類型,替代療法佔很大佔有率。

該報告分析了全球血友病市場,並概述了疾病,主要診斷和治療方法以及全球市場規模,患者人數,預測的治療藥物銷售(按類型,類型,我們正在按嚴重性(嚴重性,治療類型,治療方案),地區,主要市場促銷/限制因素,主要公司的概況等調查詳細趨勢。

目錄

第1章市場概述

  • 血友病
  • 血友病的種類
  • 徵兆和症狀
  • 血友病的診斷
  • 血友病的治療

第2章新型冠狀病毒感染(COVID-19)的影響

  • 對世界經濟的影響
  • 全球COVID-19流行率
  • 對醫療費用的影響

第3章世界市場分析

  • 全球血友病市場規模(金額基準)
  • 全球血友病市場規模,預測值(金額基準)
  • 全球血友病市場:按治療方案分類
  • 全球血友病市場:按類型
    • 血友病A的市場規模,預測值(金額基準)
    • 造血疾病A市場:按嚴重程度劃分
    • 造血系統疾病A市場:按治療類型劃分
    • 造血系統疾病A市場:按治療方案分類
    • 血友病A的市場規模,預測值:按治療方案(金額基準)
    • 血友病B的市場規模,預測值(金額基準)
    • 造血疾病B市場:按嚴重程度劃分
    • 造血疾病B市場:按治療類型劃分
    • 乙型肝病市場:按治療方案劃分
    • 血友病B的市場規模,預測值:按治療方案(金額基準)
  • 全球血友病市場:按治療
    • 替代療法:市場規模,預測值(金額基準)
    • 免疫寬容導入(ITI)療法:市場規模,預測價值(金額基準)
  • 全球血友病市場:按地區

第4章區域市場分析

  • 北美
    • 造血系統疾病的市場規模(金額基準)
    • 血友病的市場規模,預測值(金額基準)
    • 美國
      • 市場規模(金額基準)
      • 市場規模,預測值(金額基準)
      • 市場規模:按類型(金額基準)
      • 市場規模,預測值:按類型(金額基準)
      • 血友病A市場-接受治療的患者人數,預測值
      • 血友病A市場-接受預防性治療的危重患者數量
      • 血友病A市場-正在接受應對療法的重症患者數量
      • 血友病A市場-接受預防性治療的輕度和中度患者的數量
      • 血友病A市場-接受應對療法的輕度/中度患者數量
      • 血友病B市場-接受治療的患者人數,預測值
      • 血友病B市場-接受預防性治療的重症患者數
      • 血友病B市場-接受應對療法的重症患者數
      • 血友病B市場-接受預防性治療的輕度和中度患者的數量
      • 血友病B市場-接受應對治療的輕度和中度患者的數量
  • 歐洲
    • 血友病的市場規模(金額基準)
    • 血友病的市場規模,預測值(金額基準)
    • 血友病患者人數,預測值
    • 血友病A患者人數,預測值
    • 血友病B的患者人數,預測值
  • 亞太地區
    • 血友病的市場規模(金額基準)
    • 血友病的市場規模,預測值(金額基準)
  • 其他國家(RoW)
    • 血友病的市場規模(金額基準)
    • 血友病的市場規模,預測值(金額基準)

第5章市場動態

  • 生長促進因素
    • 對預防性治療的興趣與日俱增
    • 提高診斷率
    • 全球醫療費用增加
  • 主要趨勢和動向
    • 將興趣轉移到延長半衰期準備工作
    • 血友病治療新藥的開發
    • 基因治療的普及
  • 挑戰
    • 高昂的治療費用
    • 不願轉向新療法

第6章競爭情況

  • 世界市場
    • 市場收入比較:主要公司之間
    • 股票市值比較:大公司之間
    • 研發費用比較:主要公司之間
    • 全球血友病市場的佔有率結構
    • 血友病A因子VIII產品的全球市場份額:按公司劃分
    • 全球血友病A因子VIII基因治療的市場份額,預測值
    • 全球血友病B市場份額:按公司劃分
    • 全球血友病B因子IX產品市場份額,預測值
    • 全球血友病B因子IX基因治療的市場份額,預測值
    • 主要公司:主要抗血液學產品
  • 美國市場
    • 美國血友病A市場佔有率:按公司
  • 歐洲市場
    • 歐洲血友病A市場佔有率:按公司劃分

第7章公司簡介

  • Pfizer Inc.
  • Bayer Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company
  • Novo Nordisk
  • CSL Limited
目錄

The global hemophilia market is anticipated to reach US$13.86 billion in 2024, growing at a CAGR of 5.61% during the period spanning 2020-2024. The growth in the market has been driven by factors like increasing healthcare expenditure and surging identified hemophilia patient volume. The market is expected to face certain challenges such as high cost of treatment and reluctance to switch to newer therapies. To overcome these challenges, the market would witness some key trends like development of novel hemophilia treatments and rising popularity of gene therapy.

The global hemophilia market by treatment regimen can be segmented as follows: prophylaxis and on-demand. In 2019, the higher share was held by prophylaxis segment, followed by on-demand segment. The global hemophilia market by type can be segmented into the following: hemophilia A and hemophilia B, where hemophilia A held a larger share of the market in 2019. The global hemophilia market by therapy can be segmented as follows: replacement therapy and ITI therapy. The dominant share of the market in 2019 was held by replacement therapy segment. The global hemophilia market by region can be segmented into the following regions: North America, Europe and Asia Pacific.

In 2019, the dominant share of the market was held by North America, followed by Europe and Asia Pacific. The factors like rising prevalence of hemophilia, growing knowledge amongst individuals regarding different treatment methods and surging inclination towards prophylaxis treatment contributed towards growth in the North American market.

Scope of the report:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
  • The major regional markets North America, Europe and Asia Pacific with country analysis of the US have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.

Key Target Audience:

  • Hemophilia Drugs Manufacturers
  • API Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis of Hemophilia
  • 1.5 Treatment of Hemophilia

2. Impact of COVID-19

  • 2.1 Impact on Global Economy
  • 2.2 Global Prevalence of COVID-19
  • 2.3 Impact on Healthcare Spending

3. Global Market Analysis

  • 3.1 Global Hemophilia Market by Value
  • 3.2 Global Hemophilia Market Forecast by Value
  • 3.3 Global Hemophilia Market by Treatment Regimen
  • 3.4 Global Hemophilia Market by Type
    • 3.4.1 Global Hemophilia A Market Forecast by Value
    • 3.4.2 Global Hemophilia A Market by Severity
    • 3.4.3 Global Hemophilia A Market by Treatment Type
    • 3.4.4 Global Hemophilia A Market by Treatment Regimen
    • 3.4.5 Global Hemophilia A Market Value by Treatment Regimen
    • 3.4.6 Global Hemophilia B Market Forecast by Value
    • 3.4.7 Global Hemophilia B Market by Severity
    • 3.4.8 Global Hemophilia B Market by Treatment Type
    • 3.4.9 Global Hemophilia B Market by Treatment Regimen
    • 3.4.10 Global Hemophilia B Market Value by Treatment Regimen
  • 3.5 Global Hemophilia Market by Therapy
    • 3.5.1 Global Hemophilia Replacement Therapy Market Forecast by Value
    • 3.5.2 Global Hemophilia ITI Therapy Market Forecast by Value
  • 3.6 Global Hemophilia Market by Region

4. Regional Market Analysis

  • 4.1 North America
    • 4.1.1 North America Hemophilia Market by Value
    • 4.1.2 North America Hemophilia Market Forecast by Value
    • 4.1.3 The US Hemophilia Market by Value
    • 4.1.4 The US Hemophilia Market Forecast by Value
    • 4.1.5 The US Hemophilia Market by Type
    • 4.1.6 The US Hemophilia A Market Forecast by Value
    • 4.1.7 The US Hemophilia A Treated Patient Volume Forecast
    • 4.1.8 The US Hemophilia A Severe Patients on Prophylactic Therapy
    • 4.1.9 The US Hemophilia A Severe Patients on On-Demand Therapy
    • 4.1.10 The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy
    • 4.1.11 The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy
    • 4.1.12 The US Hemophilia B Market Forecast by Value
    • 4.1.13 The US Hemophilia B Treated Patients Volume Forecast
    • 4.1.14 The US Hemophilia B Severe Patients on Prophylaxis Therapy
    • 4.1.15 The US Hemophilia B Severe Patients on On-Demand Therapy
    • 4.1.16 The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy
    • 4.1.17 The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy
  • 4.2 Europe
    • 4.2.1 Europe Hemophilia Market by Value
    • 4.2.2 Europe Hemophilia Market Forecast by Value
    • 4.2.3 Europe Hemophilia Patient Volume Forecast
    • 4.2.4 Europe Hemophilia A Patient Volume Forecast
    • 4.2.5 Europe Hemophilia B Patient Volume Forecast
  • 4.3 Asia Pacific
    • 4.3.1 Asia Pacific Hemophilia Market by Value
    • 4.3.2 Asia Pacific Hemophilia Market Forecast by Value
  • 4.4 ROW
    • 4.4.1 ROW Hemophilia Market by Value
    • 4.4.2 ROW Hemophilia Market Forecast by Value

5. Market Dynamics

  • 5.1 Growth Drivers
    • 5.1.1 Increased Focus on Prophylactic Treatment
    • 5.1.2 Increasing Diagnosis Rate
    • 5.1.3 Rise in Global Healthcare Expenditure
  • 5.2 Key Trends & Development
    • 5.2.1 Shifting Focus to Extended Half Life Therapies
    • 5.2.2 Development of Novel Hemophilia Treatments
    • 5.2.3 Popularity of Gene Therapy
  • 5.3 Challenges
    • 5.3.1 High Cost of Treatment
    • 5.3.2 Reluctance to Switch to New Therapies

6. Competitive Landscape

  • 6.1 Global Market
    • 6.1.1 Revenue Comparison - Key Players
    • 6.1.2 Market Capitalization Comparison- Key Players
    • 6.1.3 Research & Development Expenses Comparison - Key Players
    • 6.1.4 Global Hemophilia A Market Share by Company
    • 6.1.5 Global Hemophilia A Factor VIII Products Market Share by Company
    • 6.1.6 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
    • 6.1.7 Global Hemophilia B Market Share by Company
    • 6.1.8 Global Hemophilia B Factor IX Products Market Share Forecast
    • 6.1.9 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
    • 6.1.10 Key Players - Major Anti-Hemophilia Products
  • 6.2 The US Market
    • 6.2.1 The US Hemophilia A Market Share by Company
  • 6.3 Europe Market
    • 6.3.1 Europe Hemophilia A Market Share by Company

7. Company Profiles

  • 7.1 Pfizer Inc.
    • 7.1.1 Business Overview
    • 7.1.2 Financial Overview
    • 7.1.3 Business Strategies
  • 7.2 Bayer Group
    • 7.2.1 Business Overview
    • 7.2.2 Financial Overview
    • 7.2.3 Business Strategies
  • 7.3 Sanofi S.A.
    • 7.3.1 Business Overview
    • 7.3.2 Financial Overview
    • 7.3.3 Business Strategies
  • 7.4 Takeda Pharmaceutical Company
    • 7.4.1 Business Overview
    • 7.4.2 Financial Overview
    • 7.4.3 Business Strategies
  • 7.5 Novo Nordisk
    • 7.5.1 Business Overview
    • 7.5.2 Financial Overview
    • 7.5.3 Business Strategies
  • 7.6 CSL Limited
    • 7.6.1 Business Overview
    • 7.6.2 Financial Overview
    • 7.6.3 Business Strategies

List of Charts

  • Types of Hemophilia
  • Diagnosis of Hemophilia
  • Global Coronavirus Prevalence (Jan'20 - Sep'20)
  • Global Hemophilia Market by Value (2015-2019)
  • Global Hemophilia Market Forecast by Value (2020-2024)
  • Global Hemophilia Market by Treatment Regimen (2019)
  • Global Hemophilia Market by Type (2019)
  • Global Hemophilia A Market Forecast by Value (2019-2024)
  • Global Hemophilia A Market by Severity (2019)
  • Global Hemophilia A Market by Treatment Type (2019)
  • Global Hemophilia A Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia A Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia B Market Forecast by Value (2019-2024)
  • Global Hemophilia B Market by Severity (2019)
  • Global Hemophilia B Market by Treatment Type (2019)
  • Global Hemophilia B Market by Treatment Regimen (2019 & 2024)
  • Global Hemophilia B Market Value by Treatment Regimen (2019-2024)
  • Global Hemophilia Market by Therapy (2019)
  • Global Hemophilia Replacement Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia ITI Therapy Market Forecast by Value (2019-2024)
  • Global Hemophilia Market by Region (2019)
  • North America Hemophilia Market by Value (2015-2019)
  • North America Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Value (2015-2019)
  • The US Hemophilia Market Forecast by Value (2020-2024)
  • The US Hemophilia Market by Type (2019)
  • The US Hemophilia A Market Forecast by Value (2019-2024)
  • The US Hemophilia A Treated Patient Volume Forecast (2019-2024)
  • The US Hemophilia A Severe Patients on Prophylactic Therapy (2019-2024)
  • The US Hemophilia A Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia A Mild to Moderate Patients on Prophylaxis Therapy (2019-2023)
  • The US Hemophilia A Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Market Forecast by Value (2019-2024)
  • The US Hemophilia B Treated Patients Volume Forecast (2019-2024)
  • The US Hemophilia B Severe Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Severe Patients on On-Demand Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on Prophylaxis Therapy (2019-2024)
  • The US Hemophilia B Mild to Moderate Patients on On-Demand Therapy (2019-2024)
  • Europe Hemophilia Market by Value (2015-2019)
  • Europe Hemophilia Market Forecast by Value (2020-2024)
  • Europe Hemophilia Patient Volume Forecast (2019-2024)
  • Europe Hemophilia A Patient Volume Forecast (2019-2024)
  • Europe Hemophilia B Patient Volume Forecast (2019-2024)
  • Asia Pacific Hemophilia Market by Value (2015-2019)
  • Asia Pacific Hemophilia Market Forecast by Value (2020-2024)
  • ROW Hemophilia Market by Value (2015-2019)
  • ROW Hemophilia Market Forecast by Value (2020-2023)
  • Global Market Share of Hemophilia A and B Patients on Prophylaxis (2019)
  • Global Identified Hemophilia Patients Volume (2012-2019)
  • Global Healthcare Expenditure (2014-2018)
  • Global Hemophilia A Market Share by Company (2019)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2019)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2023/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • The US Hemophilia A Market Share by Company (2019)
  • Europe Hemophilia B Market Share by Company (2019)
  • Pfizer Inc. Revenue and Net Income (2015-2019)
  • Pfizer Inc. Revenue by Segment (2019)
  • Pfizer Inc. Revenue by Region (2019)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Bayer Group Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales and Net Income (2014-2018)
  • Sanofi S.A. Net Sales by Segment (2019)
  • Sanofi S.A. Net Sales by Region (2019)
  • Takeda Pharmaceutical Company Revenue and Net Income (2016-2020)
  • Takeda Pharmaceutical Company Revenue by Segment (2020)
  • Takeda Pharmaceutical Company Revenue by Region (2020)
  • Novo Nordisk Net Sales and Net Profit (2014-2018)
  • Novo Nordisk Net Sales by Segment (2019)
  • Novo Nordisk Net Sales by Region (2019)
  • CSL Limited Sales Revenue and Net Profit (2016-2020)
  • CSL Limited Sales Revenue by Segment (2020)
  • CSL Limited Sales Revenue by Region (2020)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Extended Half Life Products (2019)
  • Development of New Novel Hemophilia Treatments (2019)
  • Hemophilia Gene Therapy Candidates (2018/2019)
  • Key Players - Revenue Comparison (2019/2020)
  • Key Players - Market Capitalization Comparison (2020)
  • Key Players - Research & Development Expenses Comparison (2019/2020)
  • Key Players - Main Anti-Hemophilia Products